Brief Summary

The investigators wish to test a diagnostic risk score for autoimmune encephalitis in case of encephalitis, previously validated by two American teams, in a retrospective analysis, according to the clinical and paraclinical data available in our database of the Reference Centre for Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of Professor Honnorat for patients with NMDAr, anti LGi1, anti CASPR2, anti GABAbr and anti GAD antibodies.

Trial Health

At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date

Enrollment

350

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Feb 2023

Shorter than P25 for all trials

Geographic Reach

1 country

1 active site

Status

unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

11 months study duration

Study Start

First participant enrolled

February 1, 2023

Completed

Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2023

Completed

5 months until next milestone

First Submitted

Initial submission to the registry

June 27, 2023

Completed

23 days until next milestone

First Posted

Study publicly available on registry

July 20, 2023

Completed

5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed

Last Updated

November 13, 2023

Status Verified

June 1, 2023

Enrollment Period

Same day

First QC Date

June 27, 2023

Last Update Submit

November 9, 2023

Conditions

Autoimmune Encephalitis Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)

Keywords

Diagnostic scoreauto-immune encephalitis

Outcome Measures

Primary Outcomes (6)

Validation of a diagnostic score for encephalitis to assess the risk of autoimmune origin.
Comorbidities assessed by the Charlson score
At baseline
Symptoms in the acute phase
At baseline
Mode of onset of disease
At baseline
Results of lumbar puncture
At baseline
Results of antineuronal antibodies in CSF
At baseline
Results of antineuronal antibodies in serum
At baseline

Study Arms (5)

NMDAr patients

Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies : \- Anti NMDAr